Rosen Law Firm Encourages RGNX Investors to Take Action in Securities Fraud Case
In recent news, the Rosen Law Firm has issued a reminder to investors who purchased securities of REGENXBIO, Inc. (NASDAQ: RGNX) during the period from February 9, 2022, to January 27, 2026. This communication comes in light of a class action lawsuit focused on allegations of securities fraud, with a critical deadline of April 14, 2026, for those wishing to serve as lead plaintiffs.
The lawsuit pertains to concerns over misrepresentation and omissions made by REGENXBIO regarding its gene therapy product candidate, RGX-111, which targets severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. According to the allegations, while the company presented an overwhelmingly positive outlook on the potential success of RGX-111 trials, it concurrently withheld crucial information about the product’s efficacy and safety. As a result, investors could find themselves suffering financial losses when the true information was revealed.
Rosen Law Firm invites any investors affected by this situation to join the class action, which has already been initiated. Notably, joining this lawsuit does not require any upfront costs, as they operate on a contingency fee basis, meaning that fees will only be claimed from any recovery won in court.
Investors who want to participate in this class action have multiple ways to express their interest. They can visit Rosen Law Firm's website at https://rosenlegal.com/submit-form/?case_id=53421 or reach out directly by calling attorney Phillip Kim, Esq. at 866-767-3653. Alternatively, inquiries can be directed to him via email. It is crucial for potential lead plaintiffs to act promptly to meet the April 14, 2026, deadline, as this role involves directing the litigation on behalf of other class members.
The Rosen Law Firm emphasizes the importance of selecting a reputable legal team for such cases. Many firms that broadcast announcements may not actually possess the experience required to adequately handle securities class actions. The Rosen Law Firm itself has an impressive track record, being recognized for securing significant settlements in similar cases in the past, including against international companies. They have been ranked highly for their number of settlements and have secured substantial recoveries for investors over recent years.
The legal proceedings surrounding this case will likely hinge on the disclosures made by REGENXBIO about its clinical trials regarding RGX-111. If it is found that the information withheld from investors adversely impacted their financial decisions, REGENXBIO could face considerable legal repercussions.
To keep informed, interested parties can follow the Rosen Law Firm's updates on their social media channels, including LinkedIn, Twitter, and Facebook.
As the April 14 deadline approaches, it is critical for investors who purchased REGENXBIO securities during the class period to consider their options carefully. Taking swift action could lead to participation in a legal process that seeks to remedy financial damages suffered, thereby protecting shareholder interests. The relevant class action case serves as a crucial reminder of investor vigilance and the importance of transparency from companies in the biotech sector.
Understanding the Context
The lawsuit pertains to concerns over misrepresentation and omissions made by REGENXBIO regarding its gene therapy product candidate, RGX-111, which targets severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. According to the allegations, while the company presented an overwhelmingly positive outlook on the potential success of RGX-111 trials, it concurrently withheld crucial information about the product’s efficacy and safety. As a result, investors could find themselves suffering financial losses when the true information was revealed.
Rosen Law Firm invites any investors affected by this situation to join the class action, which has already been initiated. Notably, joining this lawsuit does not require any upfront costs, as they operate on a contingency fee basis, meaning that fees will only be claimed from any recovery won in court.
Steps to Take
Investors who want to participate in this class action have multiple ways to express their interest. They can visit Rosen Law Firm's website at https://rosenlegal.com/submit-form/?case_id=53421 or reach out directly by calling attorney Phillip Kim, Esq. at 866-767-3653. Alternatively, inquiries can be directed to him via email. It is crucial for potential lead plaintiffs to act promptly to meet the April 14, 2026, deadline, as this role involves directing the litigation on behalf of other class members.
The Importance of Experienced Counsel
The Rosen Law Firm emphasizes the importance of selecting a reputable legal team for such cases. Many firms that broadcast announcements may not actually possess the experience required to adequately handle securities class actions. The Rosen Law Firm itself has an impressive track record, being recognized for securing significant settlements in similar cases in the past, including against international companies. They have been ranked highly for their number of settlements and have secured substantial recoveries for investors over recent years.
Legal Proceedings and Potential Outcomes
The legal proceedings surrounding this case will likely hinge on the disclosures made by REGENXBIO about its clinical trials regarding RGX-111. If it is found that the information withheld from investors adversely impacted their financial decisions, REGENXBIO could face considerable legal repercussions.
To keep informed, interested parties can follow the Rosen Law Firm's updates on their social media channels, including LinkedIn, Twitter, and Facebook.
Conclusion
As the April 14 deadline approaches, it is critical for investors who purchased REGENXBIO securities during the class period to consider their options carefully. Taking swift action could lead to participation in a legal process that seeks to remedy financial damages suffered, thereby protecting shareholder interests. The relevant class action case serves as a crucial reminder of investor vigilance and the importance of transparency from companies in the biotech sector.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.